(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis
Status:
Completed
Trial end date:
2017-03-23
Target enrollment:
Participant gender:
Summary
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of
Escalating Doses of SAN-300 in Patients with Active Rheumatoid Arthritis with Inadequate
Response to Disease-Modifying Anti-rheumatic Drug(s).
Phase:
Phase 2
Details
Lead Sponsor:
Bausch Health Americas, Inc. Valeant Pharmaceuticals International, Inc.